Nasonex Sinus nasal spray 50 mcg/dose, 10 g (60 doses) — Made in Belgium — Free Delivery

Product description

Nasonex Sinus Nasal Spray is indicated for:

• Treatment of seasonal or perennial allergic rhinitis in adults and children over 2 years of age. It is recommended to start prophylactic treatment for moderate to severe allergic rhinitis 4 weeks before the expected start of the dusting season.
• As an auxiliary therapeutic agent in the treatment of acute sinusitis with antibiotics in adults (including the elderly) and children over 12 years of age.
• Treating symptoms of acute sinusitis without signs of severe bacterial infection in adults and children over 12 years of age.
• Treat nasal polyps and related symptoms, including nasal congestion and loss of smell, in patients over the age of 18.

Structure

Active ingredient: 1 spray dose contains mometasone furoate monohydrate (micronized) in an amount equivalent to 50 μg of mometasone furoate (anhydrous);

Excipients: dispersed cellulose (microcrystalline cellulose and sodium carboxymethyl cellulose) glycerin citric acid monohydrate, sodium, dihydrate; polysorbate 80; benzalkonium chloride solution purified water.

Contraindications

Hypersensitivity to the active substance or to any inactive component of the preparation.

Mode of application

Application features

Pregnant

Corticosteroid preparations should not be used by pregnant or breastfeeding women unless absolutely necessary.

Children

Not applicable until 2 years of age.

Overdose

It is unlikely that an overdose will require any therapy other than monitoring.

Inhalation or oral administration of excessive doses of corticosteroids can lead to suppression of the function of the hypothalamic-pituitary-adrenal system.

Side effects

Headache (8%), nosebleeds (that is, obvious bleeding, as well as bloody mucus or blood clots) (8%), pharyngitis (4%), burning sensation in the nose (2%), irritation (2%) and ulcerative changes (1%) of the nasal mucosa.

Interaction

With the simultaneous use of mometasone with CYP3A inhibitors, including preparations containing cobicistat, an increased risk of systemic adverse reactions is expected. Such combinations should be avoided, unless the expected benefit of treatment outweighs the potential risk of systemic corticosteroid adverse reactions, in such cases, systemic corticosteroid adverse reactions should be closely monitored.

Storage conditions

Store at a temperature not exceeding 25 ° C, out of the reach of children. Do not freeze.

Shelf life is 3 years.